Regulation of neuropeptide Y Y1 receptor expression by bone morphogenetic protein 2 in C2C12 myoblasts

Biochemical and Biophysical Research Communications

Volumn 439, Issue 4, 2013, Pages 506-510

  Kurebayashi, Naoko ^a   Sato, Mari ^a   Fujisawa, Toshiaki ^a   Fukushima, Kazuaki ^a   Tamura, Masato ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Bone morphogenetic protein 2; Neuropeptide Y; Osteoblasts; Y1 receptor

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; MESSENGER RNA; NEUROPEPTIDE Y; NEUROPEPTIDE Y1 RECEPTOR; OSTEOCALCIN; SMAD1 PROTEIN; SMAD4 PROTEIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR OSTERIX; TRANSCRIPTION FACTOR RUNX2;

ARTICLE; AUTOCRINE EFFECT; CELL DIFFERENTIATION; CONTROLLED STUDY; GENE ACTIVITY; GENE EXPRESSION REGULATION; GENE INDUCTION; GENE INTERACTION; GENE SILENCING; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; INTRACELLULAR SIGNALING; MOUSE; MYOBLAST; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN FUNCTION; RECEPTOR GENE; SIGNAL TRANSDUCTION; UPREGULATION;

BONE MORPHOGENETIC PROTEIN 2; NEUROPEPTIDE Y; OSTEOBLASTS; Y1 RECEPTOR;

ANIMALS; BONE MORPHOGENETIC PROTEIN 2; CELL LINE; MICE; MYOBLASTS; OSTEOBLASTS; RECEPTORS, NEUROPEPTIDE Y; RNA, MESSENGER; SIGNAL TRANSDUCTION; SMAD1 PROTEIN; SMAD4 PROTEIN;

MUS;

EID: 84884704160     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.09.014     Document Type: Article

References (34)

1. Baraban S.C. Neuropeptide Y and limbic seizures. Rev. Neurosci. 1998, 9:117-128.
2. Silva A.P., Cavadas C., Grouzmann E. Neuropeptide Y and its receptors as potential therapeutic drug targets. Clin. Chim. Acta 2002, 326:3-25.
3. Kuo L.E., Kitlinska J.B., Tilan J.U., Li L., Baker S.B., Johnson M.D., Lee E.W., Burnett M.S., Fricke S.T., Kvetnansky R., Herzog H., Zukowska Z. Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome. Nat. Med. 2007, 13:803-811.
4. Baldock P.A., Allison S.J., Lundberg P., Lee N.J., Slack K., Lin E.J., Enriquez R.F., McDonald M.M., Zhang L., During M.J., Little D.G., Eisman J.A., Gardiner E.M., Yulyaningsih E., Lin S., Sainsbury A., Herzog H. Novel role of Y1 receptors in the coordinated regulation of bone and energy homeostasis. J. Biol. Chem. 2007, 282:19092-19102.
5. Yang K., Guan H., Arany E., Hill D.J., Cao X. Neuropeptide Y is produced in visceral adipose tissue and promotes proliferation of adipocyte precursor cells via the Y1 receptor. FASEB J. 2008, 22:2452-2464.
6. Khor E.C., Baldock P. The NPY system and its neural and neuroendocrine regulation of bone. Curr. Osteoporos. Rep. 2012, 10:160-168.
7. Lin S., Boey D., Herzog H. NPY and Y receptors: lessons from transgenic and knockout models. Neuropeptides 2004, 38:189-200.
8. Allison S.J., Baldock P.A., Herzog H. The control of bone remodeling by neuropeptide Y receptors. Peptides 2007, 28:320-325.
9. Baldock P.A., Sainsbury A., Couzens M., Enriquez R.F., Thomas G.P., Gardiner E.M., Herzog H. Hypothalamic Y2 receptors regulate bone formation. J. Clin. Invest. 2002, 109:915-921.
10. Shi Y.C., Lin S., Wong I.P., Baldock P.A., Aljanova A., Enriquez R.F., Castillo L., Mitchell N.F., Ye J.M., Zhang L., Macia L., Yulyaningsih E., Nguyen A.D., Riepler S.J., Herzog H., Sainsbury A. NPY neuron-specific Y2 receptors regulate adipose tissue and trabecular bone but not cortical bone homeostasis in mice. PLoS One 2010, 5:e11361.
11. Lundberg P., Allison S.J., Lee N.J., Baldock P.A., Brouard N., Rost S., Enriquez R.F., Sainsbury A., Lamghari M., Simmons P., Eisman J.A., Gardiner E.M., Herzog H. Greater bone formation of Y2 knockout mice is associated with increased osteoprogenitor numbers and altered Y1 receptor expression. J. Biol. Chem. 2007, 282:19082-19091.
12. Igwe J.C., Jiang X., Paic F., Ma L., Adams D.J., Baldock P.A., Pilbeam C.C., Kalajzic I. Neuropeptide Y is expressed by osteocytes and can inhibit osteoblastic activity. J. Cell. Biochem. 2009, 108:621-630.
13. Lee N.J., Doyle K.L., Sainsbury A., Enriquez R.F., Hort Y.J., Riepler S.J., Baldock P.A., Herzog H. Critical role for Y1 receptors in mesenchymal progenitor cell differentiation and osteoblast activity. J. Bone Miner. Res. 2010, 25:1736-1747.
14. Canalis E., Economides A., Gazzerro E. Bone morphogenetic proteins, their antagonists, and the skeleton. Endocr. Rev. 2003, 24:218-235.
15. Katagiri T., Yamaguchi A., Komaki M., Abe E., Takahashi N., Ikeda T., Rosen V., Wozney J., Fujisawa-Sehara A., Suda T. Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage. J. Cell Biol. 1994, 127:1755-1766.
16. Miyazawa K., Shinozaki M., Hara T., Furuya T., Miyazono K. Two major Smad pathways in TGF-beta superfamily signalling. Genes Cells 2002, 7:1191-1204.
17. Shi Y., Massagué J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003, 113:685-700.
18. Nakashima A., Katagiri T., Tamura M. Cross-talk between Wnt and bone morphogenetic protein 2 (BMP-2) signaling in differentiation pathway of C2C12 myoblasts. J. Biol. Chem. 2005, 280:37660-37668.
19. Katagiri T., Imada M., Yanai T., Suda T., Takahashi N., Kamijo R. Identification of a BMP-responsive element in Id1, the gene for inhibition of myogenesis. Genes Cells 2002, 7:949-960.
20. Nojima J., Kanomata K., Takada Y., Fukuda T., Kokabu S., Ohte S., Takada T., Tsukui T., Yamamoto T.S., Sasanuma H., Yoneyama K., Ueno N., Okazaki Y., Kamijo R., Yoda T., Katagiri T. Dual roles of Smad proteins in the conversion from myoblasts to osteoblastic cells by bone morphogenetic proteins. J. Biol. Chem. 2010, 285:15577-15586.
21. Sato M., Nakashima A., Nashimoto M., Yawaka Y., Tamura M. Bone morphogenetic protein-2 enhances Wnt/beta-catenin signaling-induced osteoprotegerin expression. Genes Cells 2009, 14:141-153.
22. Uyama M., Sato M.M., Kawanami M., Tamura M. Regulation of osteoblastic differentiation by the proteasome inhibitor bortezomib. Genes Cells 2012, 17:548-558.
23. Tang S.J., Hoodless P.A., Lu Z., Breitman M.L., McInnes R.R., Wrana J.L., Buchwald M. The Tlx-2 homeobox gene is a downstream target of BMP signalling and is required for mouse mesoderm development. Development 1998, 125:1877-1887.
24. Dennler S., Itoh S., Vivien D., ten Dijke P., Huet S., Gauthier J.M. Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J. 1998, 17:3091-3100.
25. Eva C., Oberto A., Sprengel R., Genazzani E. The murine NPY-1 receptor gene. Structure and delineation of tissue-specific expression. FEBS Lett. 1992, 314:285-288.
26. Quarles L.D., Yohay D.A., Lever L.W., Caton R., Wenstrup R.J. Distinct proliferative and differentiated stages of murine MC3T3-E1 cells in culture: an in vitro model of osteoblast development. J. Bone Miner. Res. 1992, 7:683-692.
27. Mannon P.J., Kaiser L.M. Retinoic acid is a negative regulator of the neuropeptide Y/peptide YY Y1 receptor gene in SK-N-MC cells. J. Neurochem. 1997, 68:20-25.
28. Kusanagi K., Inoue H., Ishidou Y., Mishima H.K., Kawabata M., Miyazono K. Characterization of a bone morphogenetic protein-responsive Smad-binding element. Mol. Biol. Cell 2000, 11:555-565.
29. Zawel L., Dai J.L., Buckhaults P., Zhou S., Kinzler K.W., Vogelstein B., Kern S.E. Human Smad3 and Smad4 are sequence-specific transcription activators. Mol. Cell 1998, 1:611-617.
30. Johnson K., Kirkpatrick H., Comer A., Hoffmann F.M., Laughon A. Interaction of Smad complexes with tripartite DNA-binding sites. J. Biol. Chem. 1999, 274:20709-20716.
31. Teixeira L., Sousa D.M., Nunes A.F., Sousa M.M., Herzog H., Lamghari M. NPY revealed as a critical modulator of osteoblast function in vitro: new insights into the role of Y1 and Y2 receptors. J. Cell. Biochem. 2009, 107:908-916.
32. Matic I., Matthews B.G., Kizivat T., Igwe J.C., Marijanovic I., Ruohonen S.T., Savontaus E., Adams D.J., Kalajzic I. Bone-specific overexpression of NPY modulates osteogenesis. J. Musculoskelet. Neuronal Interact. 2012, 12:209-218.
33. Karsenty G. Transcriptional control of skeletogenesis. Annu. Rev. Genomics Hum. Genet. 2008, 9:183-196.
34. Sousa D.M., Baldock P.A., Enriquez R.F., Zhang L., Sainsbury A., Lamghari M., Herzog H. Neuropeptide Y Y1 receptor antagonism increases bone mass in mice. Bone 2012, 51:8-16.